NCT07209111View on ClinicalTrials.gov

A Clinical Study of MK-1084 in People With Advanced Solid Tumors (MK-1084-014)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

November 24, 2025

Primary Completion Date

April 9, 2032

Study Completion Date

April 9, 2032

Conditions

Neoplasm Malignant

Interventions

DRUG

MK-1084

Oral administration

BIOLOGICAL

Cetuximab

Intravenous administration

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY